AKE FOREST, Ill., May 16, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced results of two preclinical studies of JAG101 in two different animal models of Type 1 galactosemia. Results showed that low and high doses of intravenous JAG101 given as a one-time gene replacement therapy reduced levels of toxic metabolites in brain and liver tissues and increased GALT enzyme expression and activity in tissues relevant to long-term outcomes in Type 1 galactosemia.

LAKE FOREST, Ill., Dec. 14, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for sizeable patient populations suffering from severe genetic diseases, today announced additional details, including target genes, for its initial preclinical pipeline programs: JAG101 for Type 1 galactosemia; JAG201 for a genetic cause of autism spectrum disorder (ASD) and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and JAG301 for Type 1 diabetes.

LAKE FOREST, Ill., April 13, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.